Skip to main content

CAR T-cell and Bispecific Therapies: Clinical Applications and Nursing Management

April 26, 2024

Live symposium being held during the Oncology Nursing Society’s (ONS) 49th Annual Congress

New In-Person Event: Pre-Registration Required 

Live symposium being held during the Oncology Nursing Society’s (ONS) 49th Annual Congress*
*Participants must be registered for the ONS Annual Congress in order to attend this session:

Presentation and lunch: 12:15 – 1:45 pm ET

Marriott Marquis Washington DC
Marquis Ballroom Salon 6-10, Meeting Level 2 (M2)
901 Massachusetts Avenue
Washington, DC

Target Audience

This CE activity is intended for oncology nurses and nurse practitioners involved in the care of patients with hematologic malignancies. 


Compete with your colleagues to win prizes and earn free CE credit, as you expand your knowledge on the availability and application of CAR T-cell and bispecific therapies to treat patients with hematologic malignancies. Follow a patient from diagnosis, though therapy, and follow-up monitoring while providing input on the patient’s care! Learn about the newest treatments, safety and efficacy, patient management, barriers to access/care, resources for patient education and support from The Leukemia & Lymphoma Society, and more, in this interactive session, all to improve patient care! 

Learning Objectives

Upon completion, participants should be better able to:

  • Describe the role of CAR T- cell therapy and bispecifics in treating blood cancer
  • Apply knowledge of communication strategies, streamlined patient assessment, disparities in care, and strategies for multidisciplinary teams to improve patient-centered care
  • Explain data surrounding CAR T-cell and bispecific therapies including their proper application, efficacy, and adverse events, and resources to support patients and their caregivers
  • Optimize patient assessment to ensure effective, individualized patient care including implementation of bridging therapy when indicated 
  • Utilize appropriate tools to properly assess risk for progression and response to cellular therapies


Jessica R. Kassay-McAllister, DNP, RN, AGACNP-BC 
Oncology APP Manager
Division of Hematology/Oncology
Cellular Therapy/Stem Cell Transplant Program, Effector Cell NP
UVA School of Nursing Clinical Faculty
University of Virginia Comprehensive Cancer Center
Charlottesville, VA

Krithika Shanmugasundaram, MD
Assistant Professor of Medicine, Division of Hematology/Oncology
University of Virginia Comprehensive Cancer Center
Charlottesville, VA

Dan T. Vogl, MD, MSCE
Director, Abramson Cancer Center Clinical Research Unit
Associate Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Continuing Education Information

For Nurses
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing. 

ILNA Recertification Points
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care of the Pediatric Hematology and Oncology Patient (CPHON), Cellular Collection, Preparative Regimens, and Infusion (BMTCN), Early Post-Transplant Management and Education (BMTCN), Foundations of Transplant (BMTCN), Late Post-Transplant Management and Education (BMTCN), Oncologic Emergencies (OCN, CPHON, AOCNP), Professional Practice/Performance (BMTCN, AOCNP), Psychosocial Dimensions of Care (AOCNP, CPHON, ONC, CBCN), Quality of Life (BMTCN), Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP), Transplant Process and Infusion (BMTCN), Treatment (OCN, CBCN, AOCNP, CPHON). 
Total points: 1.5*
*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.


This activity is provided by The Leukemia & Lymphoma Society. 

Meeting space has been assigned to provide a symposium supported by The Leukemia & Lymphoma Society during the Oncology Nursing Society’s (ONS) 49th Annual Congress, April 24-April 28, 2024 in Washington, DC. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement. 


Supported by an educational grant from Bristol Myers Squibb.


For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at